BR0012748A - Análogo super-ativo do hormÈnio de lberação do hormõnio do crescimento porcino - Google Patents

Análogo super-ativo do hormÈnio de lberação do hormõnio do crescimento porcino

Info

Publication number
BR0012748A
BR0012748A BR0012748-5A BR0012748A BR0012748A BR 0012748 A BR0012748 A BR 0012748A BR 0012748 A BR0012748 A BR 0012748A BR 0012748 A BR0012748 A BR 0012748A
Authority
BR
Brazil
Prior art keywords
growth
hormone
growth hormone
animal
analog
Prior art date
Application number
BR0012748-5A
Other languages
English (en)
Inventor
Robert J Schwartz
Ruxandra Draghia-Akli
Original Assignee
Baylor College Of Medcine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Of Medcine filed Critical Baylor College Of Medcine
Publication of BR0012748A publication Critical patent/BR0012748A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Feed For Specific Animals (AREA)

Abstract

"ANáLOGO SUPER-ATIVO DO HORMÈNIO DE LIBERAçãO DO HORMÈNIO DO CRESCIMENTO PORCINO". Crescimento inadequado devido a deficiências no hormónio do crescimento (GR) , no hormónio de liberação do hormónio do crescimento (GHRH) ou devido a doenças genéticas pode ser melhorado utilizando terapia com proteina recombinante com um GHRH análogo novo apresentando uma seq³ência da SEQ ID NO:1). Também está incluído: (1) um método de tratamento das deficiências relacionadas ao hormónio de crescimento associado com a via do hormónio do crescimento; (2) um método para tratamento das deficiências relacionadas ao hormónio do crescimento associado com doenças genéticas; (3) um método para melhorar o desempenho do crescimento em um animal; (4) um método para tratamento de um animal com uma doença de deficiência de crescimento; (5) um método para aumentar a eficiência de um animal utilizado para consumo; e (6) um método para intensificar o crescimento em um animal.
BR0012748-5A 1999-07-26 2000-07-24 Análogo super-ativo do hormÈnio de lberação do hormõnio do crescimento porcino BR0012748A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14562499P 1999-07-26 1999-07-26
PCT/US2000/020127 WO2001006988A2 (en) 1999-07-26 2000-07-24 Super-active porcine growth hormone releasing hormone analog

Publications (1)

Publication Number Publication Date
BR0012748A true BR0012748A (pt) 2003-06-10

Family

ID=22513900

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012748-5A BR0012748A (pt) 1999-07-26 2000-07-24 Análogo super-ativo do hormÈnio de lberação do hormõnio do crescimento porcino

Country Status (13)

Country Link
US (3) US6551996B1 (pt)
EP (1) EP1204321B1 (pt)
JP (1) JP4644402B2 (pt)
KR (1) KR20020047096A (pt)
CN (1) CN1635898A (pt)
AT (1) ATE309358T1 (pt)
AU (1) AU772752B2 (pt)
BR (1) BR0012748A (pt)
CA (1) CA2378943C (pt)
DE (1) DE60023906T2 (pt)
MX (1) MXPA02000938A (pt)
PL (1) PL366132A1 (pt)
WO (1) WO2001006988A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
US20030074679A1 (en) * 2000-12-12 2003-04-17 Schwartz Robert J. Administration of nucleic acid sequence to female animal to enhance growth in offspring
AR035671A1 (es) * 2000-12-12 2004-06-23 Advisys Inc Administracion de secuencia de acido nucleico a un animal hembra, para aumentar el crecimiento de la descendencia
EP1578901A4 (en) * 2001-09-07 2006-03-29 Baylor College Medicine LINEAR DNA FRAGMENTS FOR GENE EXPRESSION
AR037038A1 (es) 2001-10-26 2004-10-20 Baylor College Medicine Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
CA2469310C (en) 2001-12-11 2013-01-29 Advisys, Inc. Plasmid mediated supplementation for treating chronically ill subjects
WO2003066825A2 (en) * 2002-02-07 2003-08-14 Baylor College Of Medicine Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
MXPA04011766A (es) * 2002-05-28 2005-03-31 Advisys Inc SUMINISTRO AUMENTADO DE UNA CONSTRUCCION DE áCIDO NUCLEICO IN VIVO POR EL SISTEMA DE POLO-L-GLUTAMATO (PLG).
AU2003249208B2 (en) * 2002-07-16 2010-03-04 Vgx Pharmaceuticals, Llc Codon optimized synthetic plasmids
JP2006504694A (ja) * 2002-09-18 2006-02-09 サントル・オスピタリエ・ドゥ・リュニヴェルシテ・ドゥ・モントリオール・（シー・エイチ・ユー・エム） Ｇｈｒｈ類似体
CA2513743C (en) * 2003-01-28 2013-06-25 Advisys, Inc. Reducing culling in herd animals growth hormone releasing hormone (ghrh)
CA2575926C (en) * 2003-08-04 2014-02-25 Advisys, Inc. Canine specific growth hormone releasing hormone
US7442673B2 (en) * 2003-08-15 2008-10-28 Crompton Corporation Reaction products of mercaptobenzothiazoles, mercaptothiazolines, and mercaptobenzimidazoles with epoxides as lubricant additives
CA2592891C (en) * 2003-12-31 2013-05-28 Advisys, Inc. Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation
US20090005333A1 (en) * 2004-01-26 2009-01-01 Vgx Pharmaceuticlas, Inc. Reducing culling in herd animals growth hormone releasing hormone (ghrh)
US7846720B2 (en) * 2005-01-26 2010-12-07 Vgx Pharmaceuticals, Inc. Optimized high yield synthetic plasmids
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
US8226468B2 (en) * 2008-11-13 2012-07-24 Igt Gaming system and method including points of symbol expansion
EP2421547A1 (en) * 2009-04-20 2012-02-29 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
EP2421548A4 (en) * 2009-04-20 2012-09-26 Theratechnologies Inc USE OF (HEXENOYL-TRANS-3) HGRF (L-44) NH2 AND SIMVASTATIN IN COMBINATION THERAPY
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
WO2013059525A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
US8993316B2 (en) 2011-11-16 2015-03-31 Brian P. Hanley Methods and compositions for gene therapy and GHRH therapy
CN102516364B (zh) * 2011-12-26 2013-11-06 吉林农业大学 一种模拟猪生长激素样的活性肽及制备方法与应用
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
CN108912211A (zh) 2012-02-15 2018-11-30 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
DK3445778T3 (da) 2016-04-19 2020-10-12 Griffon Pharmaceuticals Int Sa Pegylerede bioaktive peptider og anvendelser deraf
CN112724260B (zh) * 2021-01-15 2021-11-30 安徽中起生物科技有限公司 一种脂质体包封的重组兽用促生长蛋白及其制备方法和应用
CN113582881B (zh) * 2021-07-29 2022-10-11 浙江新码生物医药有限公司 一种非天然氨基酸及其应用、包含其的重组蛋白以及重组蛋白偶联物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410512A (en) 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US5036045A (en) 1985-09-12 1991-07-30 The University Of Virginia Alumni Patents Foundation Method for increasing growth hormone secretion
US4839344A (en) 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
USRE33699E (en) 1987-07-09 1991-09-24 International Minerals & Chemical Corp. Growth hormone-releasing factor analogs
US5023322A (en) 1988-08-31 1991-06-11 Mta Kutatas-Es Szervezetelemzo Intezete Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
US5084442A (en) 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5137872A (en) 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
WO1991011522A1 (en) 1990-01-26 1991-08-08 Baylor College Of Medicine MUTATED PROMOTER REGION FROM CHICKEN SKELETAL α-ACTIN GENE
CA2085362A1 (en) * 1990-06-29 1991-12-30 Arthur M. Felix Histidine substituted growth hormone releasing factor analogs
US5486505A (en) 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
EP0542937A1 (en) * 1991-04-09 1993-05-26 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
AU683121B2 (en) * 1993-12-23 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
EP0820296A4 (en) 1995-04-14 1999-06-30 Univ Tulane ANALOGS OF THE GROWTH HORMONE-RELEASING FACTOR
US6123964A (en) * 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
JPH11513989A (ja) * 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進薬の湿式造粒製剤
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6221617B1 (en) * 1996-12-06 2001-04-24 Julie Heinrich Bioassay for growth hormone releasing hormone
AU7906998A (en) * 1997-06-20 1999-01-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6127341A (en) 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2297375A1 (en) * 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use
EP1259265B1 (en) * 2000-03-03 2011-06-01 Genetronics, Inc. Nucleic acid formulations for gene delivery

Also Published As

Publication number Publication date
WO2001006988A3 (en) 2001-08-09
EP1204321A4 (en) 2002-11-06
JP2003517294A (ja) 2003-05-27
EP1204321A2 (en) 2002-05-15
DE60023906T2 (de) 2006-07-20
KR20020047096A (ko) 2002-06-21
WO2001006988A2 (en) 2001-02-01
US20030129172A1 (en) 2003-07-10
CN1635898A (zh) 2005-07-06
US6551996B1 (en) 2003-04-22
JP4644402B2 (ja) 2011-03-02
EP1204321B1 (en) 2005-11-09
ATE309358T1 (de) 2005-11-15
AU772752B2 (en) 2004-05-06
CA2378943C (en) 2012-09-18
AU6607800A (en) 2001-02-13
PL366132A1 (en) 2005-01-24
US7166461B2 (en) 2007-01-23
CA2378943A1 (en) 2001-02-01
US20030148948A1 (en) 2003-08-07
DE60023906D1 (de) 2005-12-15
MXPA02000938A (es) 2004-03-19

Similar Documents

Publication Publication Date Title
BR0012748A (pt) Análogo super-ativo do hormÈnio de lberação do hormõnio do crescimento porcino
ATE125869T1 (de) Wachstumshormonfusionsproteine.
ATE482712T1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
ATE319827T1 (de) Polypeptid, das die differenzierung unterdrueckt
CO4830493A1 (es) Anticuerpos contra cd40 humano
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
ATE257859T1 (de) Humanes, rekombinantes interferon-beta mit verbesserter löslichkeit
SI1487482T1 (sl) DNA cepivo proti proliferajočim endotelijskim celicam in postopki za uporabo le-tega
BR0107544A (pt) Composição de promoção de secreção de bile
DE60036555D1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
EP1316318A3 (en) Method of transducing a protein into cells
SE9802454D0 (sv) Production of peptides
MXPA01011158A (es) Factor de crecimiento homologo zvegf4.
AU7546500A (en) Designing immunogens
ATE346863T1 (de) Verwendung von eif4e-bindungsreagenzien in der therapie
EP1557466A4 (en) TUMOR ANTIGEN PROTEIN AND USE THEREOF
ATE399794T1 (de) Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
GB0422989D0 (en) Methods and agents for the treatment of cancer
MXPA02000801A (es) Homologo humano de polinucleotidos, nesp55 de proteina secretora de neuroendocrino bovino y usos el mismo relacionado con la obesidad.
EP0191869A4 (en) FISH CALCITONIN DERIVATIVE, PREPARATION METHOD THEREOF, AND RELATIVE GENE SYSTEM.
GB0203213D0 (en) Recombinant microorganisms
GB0209384D0 (en) Peptide composition
DE602004019141D1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide
DE60138885D1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
Howell Foot and mouth disease as a limiting factor in game farming.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL. A01N 43/04, A61K 31/70, C12N 5/00, C12N 5/02, C12N 15/00, C12N 15/09, C12N 15/63, C12N 15/70, C12N 15/74 C12N 15/85, C12N 15/87, C07H 21/02, C07H 21/04.

Ipc: A61K 38/18 (2006.01), A61K 48/00 (2006.01), C12N 1

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.